# EDGAR Filing Document

**Accession Number:** 0001157601
**File Stem:** 0001410578-25-002071
**Filing Date:** 2025-9
**Character Count:** 25802
**Document Hash:** facc868c33d47cbcfd2e118273faadff
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001410578-25-002071.hdr.sgml**: 20250911

**ACCESSION NUMBER**: 0001410578-25-002071

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 16

**FILED AS OF DATE**: 20250911

**DATE AS OF CHANGE**: 20250911

**EFFECTIVENESS DATE**: 20250911

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MADRIGAL PHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0001157601
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-290192
- **FILM NUMBER:** 251308908

**BUSINESS ADDRESS:**
- **STREET 1:** 200 BARR HARBOR DRIVE, SUITE 400
- **CITY:** WEST CONSHOHOCKEN
- **STATE:** PA
- **ZIP:** 19428
- **BUSINESS PHONE:** 404-380-9263

**MAIL ADDRESS:**
- **STREET 1:** 200 BARR HARBOR DRIVE, SUITE 400
- **CITY:** WEST CONSHOHOCKEN
- **STATE:** PA
- **ZIP:** 19428

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SYNTA PHARMACEUTICALS CORP
- **DATE OF NAME CHANGE:** 20010815

**As filed with the Securities and Exchange Commission on September 11, 2025**

 **Registration No. 333-** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM S-8**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

------

**MADRIGAL PHARMACEUTICALS, INC.**

**(Exact name of registrant as specified in its charter)**

------

---

| | |
|:---|:---|
| **Delaware** | **04-3508648** |
| **(State or other jurisdiction of<br> incorporation or organization)** | **(I.R.S. Employer<br> Identification No.)** |

---

&nbsp;&nbsp;**Four Tower Bridge<br> 200 Barr Harbor Drive, Suite 200<br> West Conshohocken, Pennsylvania 19428**<br> (Address of Principal Executive Offices, Zip Code)

**MADRIGAL PHARMACEUTICALS, INC. 2025 INDUCEMENT STOCK PLAN, AS AMENDED**

(Full title of the plan)

**Mardi Dier**

**Executive Vice President and Chief Financial Officer** 

**Madrigal Pharmaceuticals, Inc.**

**Four Tower Bridge**

**200 Barr Harbor Drive, Suite 200**

**West Conshohocken, Pennsylvania 19428**

(Name and address of agent for service)

**(267) 824-2827**

(Telephone number, including area code, of agent for service)

------

***Copies to:***

**Gregg Katz, Esq.**

**Goodwin Procter LLP**

**100 Northern Avenue**

**Boston, MA 02210**

**(617) 570-1000**

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ⌧ | Accelerated filer | ◻ |
| Non-accelerated filer | ◻ | Smaller reporting company | ◻ |
|  |  | Emerging growth company | ◻ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**EXPLANATORY NOTE**

Pursuant to General Instruction E to Form S-8, this Registration Statement on Form S-8 (the "Registration Statement") is being filed by Madrigal Pharmaceuticals, Inc. (the "Registrant") to register an additional 300,000 shares of common stock, par value $0.0001 per share (the "Common Stock"), reserved and available for issuance under the 2025 Inducement Stock Plan (the "2025 Inducement Plan") of the Registrant, as amended.

On June 16, 2025, the Board of Directors of the Registrant (the "Board") adopted the 2025 Inducement Plan. The 2025 Inducement Plan was adopted without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4) and is administered by the Compensation Committee of the Board. On September 11, 2025, the Board adopted the Amendment No. 1 to the 2025 Inducement Plan, which increased the number of shares reserved and available for issuance under the 2025 Inducement Plan by 300,000 shares of Common Stock. Amendment No. 1 was adopted without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4).

The only persons eligible to receive grants of Inducement Awards (as defined below) under the 2025 Inducement Plan are individuals who satisfy the standards for inducement grants under Nasdaq Listing Rule 5635(c)(4). An "Inducement Award" means any right to receive the Registrant's common stock, cash or other property granted under the 2025 Inducement Plan (including nonqualified stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards or other stock-based awards).

This Registration Statement registers additional securities of the same class as other securities of the Registrant for which the registration statement filed on Form S-8 relating to the 2025 Inducement Plan (File No. [333-288200](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_s8.htm)) of the Registrant is effective. The information contained in the Registrant's registration statement on Form S-8 relating to the 2025 Inducement Plan (File No. [333-288200](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_s8.htm)) is hereby incorporated by reference pursuant to General Instruction E of Form S-8, except with respect to Item 8. Exhibits thereof.

**Part II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 8. Exhibits.** 

The exhibits listed on the Exhibit Index immediately preceding such exhibits are filed as part of this Registration Statement, and the contents of the Exhibit Index are incorporated herein by reference.

**EXHIBIT INDEX**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** |
| **Exhibit <br> Number** | <br>**Exhibit Description** | <br>**Filed<br> Herewith** | **Form** | **SEC File /<br> Registration Number** | **Exhibit** | **Filing Date** |
| [4.1](https://www.sec.gov/Archives/edgar/data/1157601/000104746917002260/a2231593zex-3_1.htm) | [Restated Certificate of Incorporation of the Registrant](https://www.sec.gov/Archives/edgar/data/1157601/000104746917002260/a2231593zex-3_1.htm) |  | [10-K](https://www.sec.gov/Archives/edgar/data/1157601/000104746917002260/a2231593zex-3_1.htm) | [001-33277](https://www.sec.gov/Archives/edgar/data/1157601/000104746917002260/a2231593zex-3_1.htm) | [3.1](https://www.sec.gov/Archives/edgar/data/1157601/000104746917002260/a2231593zex-3_1.htm) | [03/31/17](https://www.sec.gov/Archives/edgar/data/1157601/000104746917002260/a2231593zex-3_1.htm) |
| [4.2](https://www.sec.gov/Archives/edgar/data/1157601/000119312523169187/d521638dex31.htm) | [Certificate of Amendment to Restated Certificate of Incorporation of the Registrant](https://www.sec.gov/Archives/edgar/data/1157601/000119312523169187/d521638dex31.htm) |  | [8-K](https://www.sec.gov/Archives/edgar/data/1157601/000119312523169187/d521638dex31.htm) | [001-33277](https://www.sec.gov/Archives/edgar/data/1157601/000119312523169187/d521638dex31.htm) | [3.1](https://www.sec.gov/Archives/edgar/data/1157601/000119312523169187/d521638dex31.htm) | [06/20/23](https://www.sec.gov/Archives/edgar/data/1157601/000119312523169187/d521638dex31.htm) |
| [4.3](https://www.sec.gov/Archives/edgar/data/1157601/000110465916111348/a16-8380_1ex3d1.htm) | [Restated Bylaws of the Registrant](https://www.sec.gov/Archives/edgar/data/1157601/000110465916111348/a16-8380_1ex3d1.htm) |  | [8-K](https://www.sec.gov/Archives/edgar/data/1157601/000110465916111348/a16-8380_1ex3d1.htm) | [001-33277](https://www.sec.gov/Archives/edgar/data/1157601/000110465916111348/a16-8380_1ex3d1.htm) | [3.1](https://www.sec.gov/Archives/edgar/data/1157601/000110465916111348/a16-8380_1ex3d1.htm) | [04/14/16](https://www.sec.gov/Archives/edgar/data/1157601/000110465916111348/a16-8380_1ex3d1.htm) |
| [5.1](tm2525766d1_ex5-1.htm) | [Opinion of Goodwin Procter LLP](tm2525766d1_ex5-1.htm) | [X](tm2525766d1_ex5-1.htm) |  |  |  |  |
| [23.1](tm2525766d1_ex5-1.htm) | [Consent of Goodwin Procter LLP (included in opinion of counsel filed as Exhibit 5.1)](tm2525766d1_ex5-1.htm) | [X](tm2525766d1_ex5-1.htm) |  |  |  |  |
| [23.2](tm2525766d1_ex23-2.htm) | [Consent of PricewaterhouseCoopers LLP](tm2525766d1_ex23-2.htm) | [X](tm2525766d1_ex23-2.htm) |  |  |  |  |
| [24](#a_001) | [Power of Attorney to file future amendments (set forth on the signature page of this Registration Statement)](#a_001) | [X](#a_001) |  |  |  |  |
| [99.1](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_ex99-1.htm) | [2025 Inducement Plan](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_ex99-1.htm) |  | [S-8](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_ex99-1.htm) | [333-288200](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_ex99-1.htm) | [99.1](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_ex99-1.htm) | [06/20/25](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_ex99-1.htm) |
| [99.2](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_ex99-2.htm) | [Form of Non-Qualified Stock Option Agreement](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_ex99-2.htm) |  | [S-8](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_ex99-2.htm) | [333-288200](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_ex99-2.htm) | [99.2](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_ex99-2.htm) | [06/20/25](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_ex99-2.htm) |
| [99.3](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_ex99-3.htm) | [Form of Restricted Stock Unit Award Agreement (Non-Section 16 Officers)](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_ex99-3.htm) |  | [S-8](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_ex99-3.htm) | [333-288200](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_ex99-3.htm) | [99.3](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_ex99-3.htm) | [06/20/25](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_ex99-3.htm) |
| [99.4](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_ex99-4.htm) | [Form of Restricted Stock Unit Award Agreement (Section 16 Officers)](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_ex99-4.htm) |  | [S-8](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_ex99-4.htm) | [333-288200](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_ex99-4.htm) | [99.4](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_ex99-4.htm) | [06/20/25](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_ex99-4.htm) |
| [99.5](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_ex99-5.htm) | [Form of Performance-Based Restricted Stock Unit Award Agreement](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_ex99-5.htm) |  | [S-8](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_ex99-5.htm) | [333-288200](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_ex99-5.htm) | [99.5](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_ex99-5.htm) | [06/20/25](https://www.sec.gov/Archives/edgar/data/1157601/000110465925061176/tm2518336d1_ex99-5.htm) |
| [99.6](tm2525766d1_ex99-6.htm) | [Amendment No. 1 to the 2025 Inducement Plan](tm2525766d1_ex99-6.htm) | [X](tm2525766d1_ex99-6.htm) |  |  |  |  |
| [107](tm2525766d1_ex-filingfees.htm) | [Filing Fee table](tm2525766d1_ex-filingfees.htm) | [X](tm2525766d1_ex-filingfees.htm) |  |  |  |  |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in West Conshohocken, Pennsylvania, on September 11, 2025.

---

| | |
|:---|:---|
| **MADRIGAL PHARMACEUTICALS, INC.** | **MADRIGAL PHARMACEUTICALS, INC.** |
| By: | /s/ William J. Sibold |
|  | William J. Sibold |
|  | President and Chief Executive Officer |

---

**POWER OF ATTORNEY**

Each person whose signature appears below constitutes and appoints William J. Sibold and Mardi Dier, and each of them singly, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them singly, for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement of Madrigal Pharmaceuticals, Inc. and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting to the attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in or about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that the attorneys-in-fact and agents or any of each of them or their substitute may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Name** | **Title** | **Date** |
| /s/ William J. Sibold | President and Chief Executive Officer and Director | September 11, 2025 |
| William J. Sibold | (Principal Executive Officer) |  |
| /s/ Mardi C. Dier | Chief Financial Officer | September 11, 2025 |
| Mardi C. Dier | (Principal Financial and Accounting Officer) |  |
| /s/ Julian C. Baker | Chairman of the Board | September 11, 2025 |
| Julian C. Baker |  |  |
| /s/ Kenneth M. Bate | Director | September 11, 2025 |
| Kenneth M. Bate |  |  |
| /s/ Raymond Cheong, M.D., Ph.D. | Director | September 11, 2025 |
| Raymond Cheong, M.D., Ph.D. |  |  |
| /s/ Daniel Brennan | Director | September 11, 2025 |
| Daniel Brennan |  |  |
| /s/ James M. Daly | Director | September 11, 2025 |
| James M. Daly |  |  |
| /s/ Paul A. Friedman, M.D. | Director | September 11, 2025 |
| Paul A. Friedman, M.D. |  |  |
| /s/ Jacqualyn A. Fouse, Ph.D. | Director | September 11, 2025 |
| Jacqualyn A. Fouse, Ph.D. |  |  |
| /s/ Richard S. Levy, M.D. | Director | September 11, 2025 |
| Richard S. Levy, M.D. |  |  |
| /s/ Rebecca Taub, M.D. | Senior Scientific and Medical Advisor and Director | September 11, 2025 |
| Rebecca Taub, M.D. |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![](tm2525766d1_ex5-1img001.jpg) | Goodwin Procter llp<br> 100 Northern Avenue<br> Boston, MA 02210<br>goodwinlaw.com<br> +1 415 733 6000 |

---

September 11, 2025

Madrigal Pharmaceuticals, Inc.

Four Tower Bridge

200 Barr Harbor Drive, Suite 200

West Conshohocken, PA 19428

Re: <u>Securities Being Registered under Registration Statement on Form S-8</u>

We have acted as your counsel in connection with your filing of a Registration Statement on Form S-8 (the "<u>Registration Statement</u>") pursuant to the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), on or about the date hereof relating to an additional 300,000 shares (the "<u>Shares</u>") of Common Stock, par value $0.0001 per share ("<u>Common Stock</u>"), of Madrigal Pharmaceuticals, Inc., a Delaware corporation (the "<u>Company</u>"), that may be issued pursuant to the Madrigal Pharmaceuticals, Inc. 2025 Inducement Stock Plan, as amended by the Amendment No. 1 thereto (as amended, the "<u>Plan</u>").

We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinion set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company.

For purposes of the opinion set forth below, we have assumed that, at the time Shares are issued, the total number of then unissued Shares, when added to the number of shares of Common Stock issued, subscribed for, or otherwise committed to be issued, does not exceed the number of shares of Common Stock authorized by the Company's certificate of incorporation.

The opinion set forth below is limited to the Delaware General Corporation Law.

Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, when delivered against payment therefor in accordance with the terms of the Plan, will be validly issued, fully paid and nonassessable.

This opinion letter and the opinion it contains shall be interpreted in accordance with the Core Opinion Principles as published in 74 *Business Lawyer* 815 (Summer 2019).

We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

---

| |
|:---|
| Very truly yours, |
| /s/ Goodwin Procter LLP |
| GOODWIN PROCTER LLP |

---

## Exhibit 23.2

**Exhibit 23.2**

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Madrigal Pharmaceuticals, Inc. of our report dated February 26, 2025 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in Madrigal Pharmaceuticals, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2024.

---

| |
|:---|
| /s/ PricewaterhouseCoopers LLP |
| Philadelphia, Pennsylvania |
| September 11, 2025 |

---

## Exhibit 99.6

**Exhibit 99.6**

**AMENDMENT NO. 1<br> TO THE <br> MADRIGAL PHARMACEUTICALS, INC.<br> 2025 INDUCEMENT STOCK PLAN**

**WHEREAS**, Madrigal Pharmaceuticals, Inc. (the "***Company***") maintains the Madrigal Pharmaceuticals, Inc. 2025 Inducement Stock Plan (the "***Plan***"), which was previously adopted by the Board of Directors of the Company (the "***Board***");

**WHEREAS**, the Board believes that the number of Shares (as defined in the Plan) remaining available for issuance under the Plan has become insufficient for the Company's anticipated future needs under the Plan;

**WHEREAS**, the Board has determined that it is advisable and in the best interest of the Company and its stockholders to amend the Plan to increase the aggregate number of Shares reserved for issuance under the Plan by 300,000 shares; and

**WHEREAS**, Section 28 of the Plan provides that the Board may amend the Plan at any time, subject to certain conditions set forth therein.

**NOW, THEREFORE**:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.** **<u>Increase in Share Pool</u>**. Section 3(a) of the Plan is hereby deleted in its entirety and replaced with the following:

"The number of Shares which may be issued from time to time pursuant to this Plan shall be 400,000 shares of Common Stock or the equivalent of such number of Shares after the Administrator, in its sole discretion, has interpreted the effect of any stock split, stock dividend, combination, recapitalization or similar transaction in accordance with Paragraph 23 of this Plan. Any of the Shares reserved and available for issuance under the Plan may be used for any type of Stock Right under the Plan."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.** **<u>Effective Date of Amendment</u>**. This Amendment to the Plan shall become effective upon the date that it is approved by the Board.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.** **<u>Other Provisions</u>**. Except as set forth above, all other provisions of the Plan shall remain unchanged.

DATE APPROVED BY BOARD OF DIRECTORS: September 11, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **MADRIGAL PHARMACEUTICALS, INC.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | Common Stock, $0.0001 par value per share | Other | 300000 | $432.30 | $129690000.00 | 0.0001531 | $19855.54 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $129690000.00  |  | $19855.54  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $19855.54  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> (1) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement on Form S-8 ("Registration Statement") shall also cover any additional shares of common stock, $0.0001 par value per share (the "Common Stock") of Madrigal Pharmaceuticals, Inc. (the "Registrant") that become issuable under the Madrigal Pharmaceuticals, Inc. 2025 Inducement Stock Plan, as amended by the Amendment No. 1 thereto (as amended, the "Plan"), by reason of any stock dividend, stock split, recapitalization or any other similar transactions. (2) Represents an increase of 300,000 shares of Common Stock available for issuance under the Plan. (3) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457 of the Securities Act, and based on $432.30, the average of the high and low sale prices of the Common Stock as reported on Nasdaq on September 5, 2025 (such date being within five business days of the date that this Registration Statement was filed with the Commission).

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---